IMDZ Overview
Upcoming Projects (IMDZ)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (IMDZ)
-
Evaluating the Clinical Evidence for CMB-305 in Soft Tissue Sarcoma
Ticker: IMDZ
Execute By: May 30, 2017
Upcoming & Overdue Catalysts (IMDZ)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (IMDZ)
-
Immune Design (IMDZ) expects Phase 2 trial data of CMB305 and Atezolizumab in Patients With Sarcoma in March 2017
Ticker: IMDZ
Occurred on: Aug 02, 2017 -
Immune Design (IMDZ) to complete Phase 1 trial of Intratumoral GLA-SE in Patients With Merkel Cell Carcinoma by January 2017
Ticker: IMDZ
Occurred on: Mar 01, 2017 -
Immune Design (IMDZ) plans to present data on G100 and ZVex vector expressing IL-12 at 2016 AICR conference
Ticker: IMDZ
Occurred on: Nov 14, 2016 -
Immune Design (IMDZ) to present data set for G100 Merkel cell carcinoma Phase 1 study at ASCO 2016
Ticker: IMDZ
Occurred on: Jun 20, 2016 -
Immune Design (IMDZ) to present preliminary data from CMB305 Phase 1 single arm study in soft tissue sarcoma patients at ASCO 2016
Ticker: IMDZ
Occurred on: Jun 05, 2016 -
Immune Design (IMDZ) announces Positive Topline Data from Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates
Ticker: IMDZ
Occurred on: Feb 09, 2016 -
Immune Design reported positive topline data from three ongoing Phase 1 oncology studies for CMB305, LV305 and G100
Ticker: IMDZ
Occurred on: Feb 09, 2016 -
Immune Design's (IMDZ) MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2
Tickers: IMDZ, AZN
Occurred on: Oct 29, 2015
Strategic Initiatives (IMDZ)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
